Brain Volume Varies Depending on Symptom Severity and Treatment Response in Schizophrenia
Abstract
Schizophrenia is a complex psychiatric disorder with varying treatment responses. This study hypothesizes that treatment-resistant schizophrenia patients exhibit distinct structural brain abnormalities compared to treatment-responsive patients and healthy controls. Identifying these differences may provide insight into the neurobiological basis of treatment resistance and guide personalized interventions. A cross-sectional study was conducted with 24 schizophrenia patients and 24 healthy controls. Schizophrenia patients were categorized into treatment responders (≥30% clinical improvement) and treatment-resistant (<30% improvement) based on clinical assessments, including standardized scales and expert evaluation. Among the scales, Positive and Negative Syndrome Scale (PANSS), The Clinical Global Impression Scale (CGI-S), The Global Assessment Scale (GAS), The Brief Psychiatric Rating Scale (BPRS) were used. Brain volumetric data were acquired using MRI and analyzed through the VolBrain platform, focusing on the frontal, temporal, and parietal lobes, cerebellum, and thalamic nuclei. Treatment-resistant demonstrated significantly reduced brain volumes in the frontal, temporal, and parietal lobes, cerebellum, and thalamic nuclei compared to responders and healthy controls (p<0.05). Additionally, treatment-resistant had higher scores on the PANSS negative symptom scale and the BPRS, indicating more severe clinical symptoms (p<0.05). Responders showed less pronounced volumetric reductions and more favorable clinical profiles. This study reveals that treatment-resistant schizophrenia is associated with marked structural brain abnormalities, particularly in regions critical for cognitive and emotional processing. These findings underscore the potential role of neuroanatomical biomarkers in predicting treatment response and highlight the necessity for targeted therapeutic strategies for treatment-resistant patients.
Keywords
Ethical Statement
This study was conducted with the approval of the Atatürk University, Faculty of Medicine Clinical Research Ethics Committee, under the ethics committee decision numbered B.30.2.ATA.0.01.00/805, dated October 26, 2023.
References
- Arathil, P., Bansal, R., & Kuruppath, A. (2024). Predicting the Outcome of First Episode Psychosis Subjects by Assessing Dorsolateral Prefrontal Cortex Volume. Archives of Psychiatry Research: An International Journal of Psychiatry and Related Sciences, 60(1.), 31-38. . [CrossRef]
- Cheng, Y., Wang, T., Zhang, T., Yi, S., Zhao, S., Li, N., Yang, Y., Zhang, F., Xu, L., & Shan, B. (2022). Increased blood-brain barrier permeability of the thalamus correlated with symptom severity and brain volume alterations in patients with schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 7(10), 1025-1034. [CrossRef] [PubMed]
- Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatric Disease and Treatment, 519-534. [CrossRef] [PubMed]
- Deniz, G., Karakurt, N., Özcan, H., & Acer, N. (2023). Comparison of brain volume measurements in methamphetamine use disorder with healthy individuals using volbrain method. Journal of Health Sciences of Adıyaman University, 9(3), 188-198. [CrossRef]
- Deniz, G., Karakurt, N., Özcan, H., & Acer, N. (2024). Comparison of detailed brain volume measurements in schizophrenia with healthy individuals. Kastamonu Medical Journal, 4(2), 52-61. [CrossRef]
- Deniz, G., Yalçın, A., Yıldırım, E., & Tan, H. (2024). Evaluation of Lesion Burden in Pediatric Patients with Multiple Sclerosis by Computer Aided Algorithm and Comparison with Standard Detection Methods. Journal of Harran University Medical Faculty, 21(2), 159-165. [CrossRef]
- Dönmezler, S., Sönmez, D., Yılbaş, B., Öztürk, H. İ., İskender, G., & Kurt, İ. (2024). Thalamic nuclei volume differences in schizophrenia patients and healthy controls using probabilistic mapping: A comparative analysis. Schizophrenia Research, 264, 266-271. [CrossRef] [PubMed]
- Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33(6), 766-771. [CrossRef] [PubMed]
- Guy, W. (1976). ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service. [CrossRef]
- He, H., Luo, C., Luo, Y., Duan, M., Yi, Q., Biswal, B. B., & Yao, D. (2019). Reduction in gray matter of cerebellum in schizophrenia and its influence on static and dynamic connectivity. Human Brain Mapping, 40(2), 517-528. [CrossRef] [PubMed]